{"analyses":[{"ciLowerLimit":"0.8","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.9","estimateComment":"The odds ratio between eribulin and dacarbazine was calculated by stratified CMH method. The stratified factors were as described above. The 2-sided 95% CI of the odds ratio is based on asymptotic normal approximation.","groupDescription":"The PFR12wks was compared between the treatment arms using stratified Cochran-Mantel-Haenszel (CMH) chi-square test stratified by histology, geographic region, and number of prior regimens for advanced STS.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.253","pValueComment":"The P-value was calculated using the stratified CMH method, the stratified factors included histology, geographic region, and number of prior regimens for advanced STS.","paramType":"Odds Ratio (OR)","paramValue":"1.3","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.2","upperLimit":"39.9","value":"33.3"},{"groupId":"OG001","lowerLimit":"22.8","upperLimit":"35.0","value":"28.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"224"}],"units":"Participants"}],"description":"The PFR12wks was defined as the percentage of participants who were still alive without disease progression at 12 weeks from the date of randomization. Tumor assessment by the investigator or designee was based on RECIST criteria 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Eribulin mesylate at a dose of 1.4 mg/m\\^2 was administered IV as a bolus infusion over 2-5 minutes on Days 1 and 8 of every 21-day treatment cycle.","id":"OG000","title":"Arm A: Eribulin Mesylate"},{"description":"Dacarbazine at a dose of 850 mg/m\\^2, 1000 mg/m\\^2, or 1200 mg/m\\^2 (as selected by the PI or designee prior to randomization according to the participant's clinical status) was administered as an IV infusion over 15-30 minutes (or up to 60 minutes as per institutional guidelines) on Day 1 of every 21-day treatment cycle.","id":"OG001","title":"Arm B: Dacarbazine"}],"paramType":"NUMBER","populationDescription":"FAS (ITT analysis set) included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"From date of randomization start until Week 12","title":"Progression-Free Rate at 12 Weeks (PFR12wks)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}